- Q
QuellTX
- Aleks Guvenel
Aleks Guvenel, PhD, is an expert in immunology and process development with extensive experience in the biopharmaceutical sector. Currently serving as Associate Director and Principal Scientist of Process Development at Quell Therapeutics since December 2020, Aleks leads the Cell Process Development team focusing on the CAR-Treg platform and manages both projects and collaborations. Prior to this role, Aleks was a Senior Cell Processing Scientist at Quell Therapeutics, finalizing large-scale process development for clinical trials. Aleks has previously held the position of Lead Scientist for Phase I/II clinical trials at UCL, where the focus was on the production of gene-modified T cells in cGMP settings. Academic training includes a PhD in Immunology, along with Master's and Bachelor's degrees from Imperial College London and King's College London, respectively. Additionally, experience at Glaxo Smith Kline as a Research Scientist involved projects related to vaccine immunology during an industrial placement.
Org chart
This person is not in the org chart
Teams
This person is not in any teams
Offices
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
